<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1671">
  <stage>Registered</stage>
  <submitdate>29/08/2007</submitdate>
  <approvaldate>29/08/2007</approvaldate>
  <nctid>NCT00523042</nctid>
  <trial_identification>
    <studytitle>Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma</studytitle>
    <scientifictitle>Inhaled Preprandial Human Insulin With the AERxÂ® iMS Versus Subcutaneous Injected Insulin Aspart in Subjects With Diabetes and Asthma: A 52-week, Open-label, Multinational, Randomised, Parallel Trial to Investigate Long-term Safety</scientifictitle>
    <utrn />
    <trialacronym>iINHALE 9</trialacronym>
    <secondaryid>NN1998-1616</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Diabetes Mellitus, Type 1</healthcondition>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - insulin aspart
Treatment: drugs - inhaled human insulin

Experimental: A - 

Active Comparator: B - 


Treatment: drugs: insulin aspart
Treat-to-target dose titration scheme, injection s.c.

Treatment: drugs: inhaled human insulin
Treat-to-target dose titration scheme, inhalation.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in lung function, chest X-rays, or asthma exacerbation frequency</outcome>
      <timepoint>after 52 weeks of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Diabetes control measured by change in HbA1c</outcome>
      <timepoint>from baseline to end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Laboratory assessments (biochemistry, insulin antibodies, blood count)</outcome>
      <timepoint>from baseline to end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preprandial insulin doses</outcome>
      <timepoint>for the duration of the trial</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type 1 or type 2 diabetes

          -  Treatment with insulin and/or oral anti-diabetic drugs

          -  Asthma for at least 6 months

          -  Positive airway reversibility/bronchoprovocation test or documented positive test in
             the last 3 years

          -  HbA1C less than or equal to 11.0 %

          -  Body Mass Index (BMI) less than or equal to 40.0 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Current smoking or smoking within the last 6 months

          -  Other current acute or chronic pulmonary disease excluding asthma

          -  Recurrent severe hypoglycaemia

          -  Proliferative retinopathy or maculopathy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>30/08/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>10</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>28/02/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Novo Nordisk Investigational Site - Broadmeadow</hospital>
    <hospital>Novo Nordisk Investigational Site - Camperdown</hospital>
    <hospital>Novo Nordisk Investigational Site - Keswick</hospital>
    <hospital>Novo Nordisk Investigational Site - Box Hill</hospital>
    <hospital>Novo Nordisk Investigational Site - East Ringwood</hospital>
    <hospital>Novo Nordisk Investigational Site - Parkville</hospital>
    <hospital>Novo Nordisk Investigational Site - Auchenflower</hospital>
    <hospital>Novo Nordisk Investigational Site - Kippa Ring</hospital>
    <postcode>2292 - Broadmeadow</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>5035 - Keswick</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3135 - East Ringwood</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>4066 - Auchenflower</postcode>
    <postcode>4021 - Kippa Ring</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Former Serbia and Montenegro</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Punjab</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tamil Nadu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>West Bengal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Hyderabad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Pune</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Cheras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kota Bharu, Kelantan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Pulau Pinang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Kosice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>L'ubochna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Moldava nad Bodvou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Zilina</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted in Europe, Asia, Oceania and the United States of America (USA).

      This is a one-year clinical trial to compare the safety of inhaled preprandial human insulin
      to subcutaneous insulin aspart in subjects with type 1 or 2 diabetes and asthma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00523042</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>